



QP-Prostate®



QP-Prostate®
Improving cancer detection
through AI technology

Discover QP-Prostate®


Prostate cancer ranks as the second most prevalent cancer in men, posing a significant public health concern.

While MRI scans are essential for early detection, the growing demand has outpaced the number of radiology experts. This has resulted in diagnostic delays and inconsistent interpretations, with only a minority of the medical community adhering to PI-RADS v2.1 guidelines.

Introducing QP-Prostate, an AI-powered solution that streamlines radiologists' workflows. By automatically evaluating PI-RADS v2.1 compliance, segmenting the prostate gland, and identifying suspicious lesions, QP-Prostate empowers radiologists to deliver quicker and more accurate assessments, ultimately enhancing patient care.




The new prostate ecosystem platform



AI POWERED USER INTERFACE

- Seamless integration into PACS and fusion biopsy systems.
- Advanced viewing with 3D visualization.
- Editing tools enable radiologists to directly interact with the AI findings.
- Radiologist control to approve or reject AI-detected lesions.
- Structured report enhances clinical communication.

QP-Prostate[®], a suite of enhanced diagnostic capabilities



END-TO-END PROSTATE MANAGEMENT WORKFLOW

Upgraded user interface & seamless integration into PACS and fusion biopsy systems allowing a fully automated workflow.






IMAGE QUALITY ASSESSMENT

Quibim AI-QUAL™ automates the assessment of prostate MRI image quality based on the PI-QUAL v2 guidelines.




PROSTATE SEGMENTATION

Automatically segments each prostate region, including the peripheral zone, the transitional and central zone, and the seminal vesicles.



LESION DETECTION & DIAGNOSIS

QP-Prostate automatically identifies and highlights prostate regions suspicious for aggressive prostate cancer, assigning each a confidence-based classification score.



STRUCTURED REPORT

PI-RADS compliant structured report that automatically integrates AI findings with radiologist annotations.

QP-Prostate® in action

Clinical Case 01



74 YO BIOPSY PATIENT WITH PSA: 15 NG/ML.

THE RADIOLOGIST DETECTS 1 LESION:


- L1 in the middle gland peripheral zone, posteromedial/lateral area (PI-RADS 4).

QP-PROSTATE DETECTS 1 LESION:

- L1 No lesion.
- L2 Suspicious lesion.

TARGETED BIOPSY CONFIRMS 1 LESION:

- L1 Benign prostatic tissue.
- L2 Gleason score 4+3.



Clinical Case 02



72 YO - PSA: 6.3 NG/ML. DPSA: 0.12 WITHOUT

QP-PROSTATE PI-RADS 2.

2023: THE RADIOLOGIST DETECTS NO LESIONS:
(Does not have QP-Prostate).

73 YO - PSA: 7.39 NG/ML. DPSA: 0.13 WITH

QP-PROSTATE PI-RADS 4.

2024: THE RADIOLOGIST DETECTS 1 LESION:

- L1 suspicious lesion in the left TZ. (PIRADS 4).

QP-PROSTATE DETECTS 1 LESION:

- L1 Highly suspicious.

TARGETED BIOPSY CONFIRMED 1 LESION:

- L1 Gleason score 3+4.

Retrospectively QP-Prostate analyzes the 2023 study, identifying the suspicious lesion; not identified in the previous reading.

